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Metabolic substrates and nutritional status play a major role in growth hormone (GH) secre-
tion. Uncovering the mechanisms involved in GH secretion following oral glucose (OG) ad-
ministration in normal and obese patients is a pending issue.
Objective
The aim of this study was to investigate GH after OG in relation with adiposity, insulin secre-
tion and action, and ghrelin secretion in obese and healthy women, to further elucidate the
mechanism of GH secretion after OG and the altered GH secretion in obesity.
Participants and Methods
We included 64 healthy and obese women. After an overnight fast, 75 g of OG were admin-
istered; GH, glucose, insulin and ghrelin were obtained during 300 minutes. Insulin secre-
tion and action indices and the area under the curve (AUC) were calculated for GH,
glucose, insulin and ghrelin. Univariate and multivariate linear regression analyses
were employed.
Results
The AUC of GH (μg/L•min) was lower in obese (249.8±41.8) than in healthy women
(490.4±74.6), P=0.001. The AUC of total ghrelin (pg/mL•min) was lower in obese
(240995.5±11094.2) than in healthy women (340797.5±37757.5), P=0.042. There were
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significant correlations between GH secretion and the different adiposity, insulin secre-
tion and action, and ghrelin secretion indices. After multivariate analysis only ghrelin AUC
remained a significant predictor for fasting and peak GH.
Introduction
Adiposity is associated with decreased growth hormone (GH) secretion [1]. The altered somato-
troph function of obesity is not permanent; it can be reversed by a return to normal weight [1].
The most striking secretory capacity appeared when obese subjects were treated with GH-
releasing hormone (GHRH) plus GH-Releasing Peptide-6, which resulted in a massive GH re-
sponse for obese subjects [2]. Clinical trials assessing the effects of GH treatment in patients with
obesity have shown reductions in total adipose tissue mass, especially abdominal and visceral ad-
ipose tissue depots [3]. In animals, an exacerbation of the age-associated decline in pulsatile GH
secretion has been found in high-fat-fed mice, as well as dietary-induced weight gain [4].
The mechanism of altered GH secretion in obesity is unclear. Insulin has been shown to re-
duce GH secretion in the animal model [5]. In humans, low-level insulin infusions, has been
found to reduce the GH response to GHRH in a dose-dependent manner [6]. Fasting insulin
and abdominal visceral fat are important predictors of integrated 24-h GH concentrations in
healthy adults [7]. Cornford et al found that overeating induced a rapid and sustained suppres-
sion of GH secretion. The reduction in GH secretion occurred before any change in body mass
and the markedly decreased GH secretion was accompanied by an increase in plasma insulin
concentration [8]. There is strong evidence that ghrelin stimulates appetite and increases circu-
lating GH across varied patient populations [9]. Studies to determine the effects of endogenous
ghrelin on the control of GH secretion have yielded conflicting results. Avram et al. [10] did
not observe any relationship with GH under fed or fasting conditions. Koutkia et al. [11] found
that there is a significant regularity in cosecretion between ghrelin and GH in the fasting state.
Misra et al. [12] found that fasting ghrelin is an independent predictor of basal GH secretion
and GH secretory burst frequency. Nass et al [13] found that under normal conditions in sub-
jects given regular meals, endogenous acylated ghrelin acts to increase the amplitude of GH
pulses. Ghrelin secretion is decreased in obesity [14] and could be responsible for altered GH
secretion in obesity.
The oral glucose tolerance test is a clinical model to study the different indices of insulin se-
cretion and action [15, 16], and is also an excellent stimulus for evaluating ghrelin [17] and GH
secretion. There is evidence that oral glucose (OG) administration affects GH secretion, initially
decreasing and subsequently stimulating GH secretion and in human obesity GH secretion
after OG is decreased [18]. With a single test we can study insulin, GH and ghrelin secretion.
Circulating plasma ghrelin increases before a meal and decreases following the consumption of
nutrients and after OG [17]. Insulin rises after OG and has been suggested to decrease circulat-
ing ghrelin levels [19]. Enhanced acylated ghrelin suppression persists for up to 2 years after
Roux-en-Y gastric bypass, and this effect is associated with decreased android obesity and im-
proved insulin secretion [20]. Ghrelin infused to levels occurring in physiologic states such as
starvation decreases insulin secretion [21]. Therefore, a possible role for insulin as a common
regulator of circulating ghrelin and GH after OG cannot be excluded. In preliminary studies in
a small number obese and healthy women, a significant correlations between post-oral glucose
GH secretion and ghrelin secretion have been found [22], although the putative contribution of
other factors like insulin secretion and action indices or leptin were not studied in depth.
Effect of Oral Glucose Administration on GH Release
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We hypothesized that among the variables known to regulate GH secretion in obesity, it
would be possible to determine the relative importance of the predictors that contribute to GH
secretion after oral glucose in women. Our aim was to study fasting GH concentrations and
their response to OG administration in relation with adiposity, insulin secretion and action in-
dices and ghrelin secretion in obese and healthy women, in order to elucidate the hypothetical
mechanism of GH secretion after OG and the altered GH secretion in obesity.
Patients and Methods
Patients
All the studies have been conducted in accordance with the Declaration of Helsinki. The
study protocol was approved by our centre0s ethical committee (Hospital A Coruña, Xunta
de Galicia), and written informed consent was obtained from all patients and controls. We
included a total of sixty-four women in our study. Forty obese women, aged 38.9±2.0 yrs.,
with a body mass index (BMI) of 37.7±1.0 kg/m2, were studied. As a control group, we stud-
ied twenty-four healthy women, selected from a pool of volunteers available to our unit, aged
37.1±2.4 yrs., and with a BMI of 22.9±0.5 kg/m2 (selected in a 2:1 ratio). Both groups were
homogeneous and only differed in terms of their BMI. None of the obese patients or controls
had diabetes mellitus or other medical problems, nor were they taking any drugs. The sub-
jects had been eating a weight-maintaining diet for several weeks prior to the study. We spe-
cifically tell the patients that they should maintain their usual eating and exercise habits
during the previous two weeks of the study.
Study procedure
Between 08.30 and 09.00 a.m., after an overnight fast and while seated, a peripheral venous line
was obtained. Fifteen minutes later 75 g of oral glucose were administered. All of the studies
were done during the first ten days from the beginning of the menstrual period. We obtained
blood samples for glucose, insulin, GH and ghrelin at baseline (fasting) and then at 30, 60, 90,
120, 150, 180, 210, 240, 270 and 300 minutes. Basal levels of leptin and insulin-like growth fac-
tor 1(IGF-1) were also measured. All blood samples were immediately centrifuged, separated
and frozen at -80°C. Samples destined to be used for the determination of plasma ghrelin were
specifically retrieved in chilled tubes containing aprotinin and EDTA-Na, and then immediate-
ly centrifuged at 4°C., separated to aliquots and frozen at -80°C. Mid-waist circumference was
measured as the midpoint between the iliac crest and the lowest rib, with the patient in the up-
right position. Total body fat was calculated through bioelectrical impedance analysis (BIA).
The independent variables examined included: age, gender, BMI, body fat, waist circumference,
fasting glucose, fasting insulin, HOMA-IR HOMA-β, Matsuda index, Glucose area under the
secretory curve (AUC), Insulin AUC, Insulin/Glucose AUC, fasting Ghrelin, ghrelin AUC.
Assays and other methods
Serum samples were collected and stored at-80 C. Serum GH (μg/L) was measured by a solid-
phase, two-site chemiluminescent enzyme immunometric assay (Immulite, EURO/DPC)
with a sensitivity of 0.01 μg/L and with intra-assay coefficients of variation of 5.3%, 6.0% and
6.5% for low, medium and high plasma GH levels respectively; and with inter-assay coeffi-
cients of variation of 6.5%, 5.5% and 6.6% for low, medium and high plasma GH levels re-
spectively. IGF-1 (ng/mL) was determined by a chemiluminescence assay (Nichols Institute,
San Clemente, CA, USA) and with intra-assay coefficients of variation of 4.8%, 5.2% and
4.4% for low, medium and high plasma IGF-1 levels respectively; and with interassay
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coefficients of variation of 7.7%, 7.4% and 4.7% for low, medium and high plasma IGF-I lev-
els respectively. Insulin (μU/mL) was measured with a solid-phase two-site chemilumines-
cent mmunometric assay (Immulite 2000 Insulin, DPC, Los Angeles, CA, USA) and with
intra-assay coefficients of variation of 5.5%, 3.3% and 3.7% for low, medium and high plasma
insulin levels respectively; and with inter-assay coefficients of variation of 7.3%, 4.1% and
5.3% for low, medium and high plasma insulin levels respectively. Leptin (ng/mL) was mea-
sured by radioimmunoassay (Mediagnost, Tubigen, Germany) and with intra-asay and inter-
assay coefficients of variation of 5.3% and 13.6% respectively. Total ghrelin (pg/ml) was mea-
sured by a commercially available radioimmunoassay (RIA) (Linco Research Inc., St Charles,
MO, USA), specific for total ghrelin, that uses 125I-labeled ghrelin tracer and rabbit antighre-
lin serum with a specificity of 100%, with an intra-assay coefficient of variation between
3.3– 10% and an inter-assay coefficient of variation between 14.7–17.8. Plasma glucose
(mg/dL) was measured with an automatic glucose oxidase method (Roche Diagnostics,
Mannheim, Germany). All samples from a given subject were analysed in the same assay run.
Calculations
The area under the secretory curve (AUC) was calculated with the trapezoidal rule (0–300
minutes).
Insulin sensitivity (IS) was measured with the following methods: HOMA-IR with the formu-
la: fasting serum insulin (μU/mL) x fasting plasma glucose (mmol/L)/22.5; quantitative IS check
index (QUICKI) with the formula: 1/[log insulin(μU/mL) + log glucose (mg/dL)]; Matsuda
index with the formula: 10,000/
p
(fasting plasma glucose (mmol/L) x fasting plasma insulin
(μU/mL)) x (mean plasma glucose0–120 x mean plasma insulin0–120). For HOMA-IR, lower val-
ues indicate higher IS; for QUICKI andMatsuda index, higher values indicate higher IS [15, 16].
Insulin secretion was estimated using the basal insulin values by the HOMA-β: [20 x fasting in-
sulin (μU/mL)]/[fasting plasma glucose (mmol/L)– 3.5]. Total insulin secretion after oral glucose
was calculated as the AUC after oral glucose and total glucose-adjusted insulin response after oral
glucose using the ratios of the areas of the insulin and glucose curves (AUC I/G) [15, 16].
Statistical analysis
Quantitative variables were expressed as mean (standard error) and median. Mann-Whitney
test was used to compare obese and control women with respect to biochemical data, hormonal
records and insulin secretion and action indices.
Association between GH secretion indices and the different adiposity, insulin secretion, in-
sulin action and ghrelin secretion indices was analyzed by means of Spearman’s Rho correla-
tion coefficient. The linearity of associations with GH secretion indices were additionally
explored by means of penalized cubic regression splines.
In the multivariate analysis, both linear regression and generalized additive (GAM) models
were used to investigate the variables associated with different GH secretion indices. In both re-
gression analyses, fasting GH, peak GH and GH area under the curve were log-transformed be-
cause of skewness. Mathematically, in GAMmodels some covariates can be replaced by
arbitrary smooth functions, so finally they were fitted to allow for nonlinear effects detected in
some of the variables studied.
Statistical analysis was carried out using the R 2.15.1 software (R Foundation for Statistical
Computing, Vienna, Austria) and the Statistical Package for Social Sciences version 19.0 for
Windows (IBM, Armonk, NY, USA). All statistical tests were two-sided. Only p-values<0.05
were considered as statistically significant.
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Results
The age and adiposity indices (mean±SE) of the healthy control group and patients are shown
in Table 1. Waist circumference (cm) was higher in the obese women than in healthy control
women; 108.8±2.1 vs 81.8±1.4 p<0.001, for the obese patients and control respectively.
Fasting serum levels
The fasting serum levels (mean±SE) are presented in Table 1.
Fasting total ghrelin (pg/mL) levels were lower in obese women than in healthy control
women; 889.4±45.5 vs 1317.6±163.9, p = 0.026, for the obese and healthy women respectively.
Fasting IGF-1 (ng/mL) levels were lower in obese women than in healthy control women;
130.0±9.2 vs 159.5±8.7, p = 0.01, for obese and healthy women respectively.
Serum levels after oral glucose. The post-oral glucose serum levels (mean±SE) are pre-
sented in Table 1. Glucose was higher in the obese women than in the healthy control women
after the 300 min OG (Fig. 1a).
Table 1. Age, adiposity indices, fasting and after oral glucose biochemical and hormonal data, and insulin secretion and action indices (mean
±SE) in obese patients and healthy control women.
Controln = 24 Obesen = 40
Mean(SE) Median Mean(SE) Median p
Age (years) 37.1 (2.4) 34.5 38.9 (2.0) 39.5 0.390
Body mass index (kg/m2) 22.9 (0.5) 22.8 37.7 (1.0) 36.2 <0.001
Waist (cm) 81.8 (1.4) 80.5 108.8 (2.1) 109.0 <0.001
Body fat mass (kg) 20.4 (1.3) 19.1 44.4 (2.0) 41.5 <0.001
Body fat (%) 30.3 (0.8) 29.2 45.3 (0.7) 45.1 <0.001
Fasting Glucose (mg/dL) 90.0 (2.0) 92.0 101.7 (2.7) 97.0 0.002
Fasting Insulin (μUI/mL) 5.3 (1.0) 4.3 15.1 (4.2) 10.6 <0.001
Fasting GH (μg/L) 2.1 (0.6) 0.7 0.9 (0.2) 0.5 0.152
Fasting IGF-1 (ng/mL) 159.5 (8.7) 160.5 130.0 (9.2) 120.5 0.010
Fasting Leptin (ng/mL) 22.8 (2.2) 20.3 67.3 (4.5) 67.3 <0.001
Fasting Ghrelin (pg/mL) 1317.6 (163.9) 1054.5 889.4 (45.5) 883.5 0.026
Peak GH (μg/L) 6.6 (0.8) 4.9 3.3 (0.5) 2.2 <0.001
AUC0–300 GH (μg/Lmin) 490.4 (74.6) 373.3 249.8 (41.8) 166.9 0.001
Peak Glucose (mg/dL) 153.2 (7.3) 149.0 174.7 (8.6) 160.5 0.155
AUC0–300 Glucose (mg/dLmin) 28718.7 (1072.0) 29370.0 33794.2 (1574.8) 31725.0 0.005
Peak Insulin (μUI/mL) 61.3 (8.4) 49.7 100.7 (9.3) 80.6 0.001
AUC0–300 Insulin (μUI/mLmin) 7668.2 (1125.6) 6385 12392.6 (947.9) 11173.0 <0.001
HOMA-β 67.4 (8.9) 67.5 111.6 (10.6) 103.9 0.008
AUC0–300 Insulin/glucose (μUI/mL)/ (mg/dL)min 0.23 (0.02) 0.2 0.4 (0.03) 0.3 <0.001
HOMAir 1.2 (0.2) 0.8 2.9 (0.3) 2.5 <0.001
QUICKI 0.4 (0.01) 0.4 0.3 (0.01) 0.3 <0.001
Matsuda Index 13.1 (1.1) 12.4 5.3 (0.4) 4.8 <0.001
Nadir ghrelin (pg/mL) 886.1 (100.1) 756.0 660.0 (35.4) 684.0 0.124
AUC0–300 ghrelin (pg/mLmin) 340797.5 (37757.5) 280372.5 240995.5 (11094.2) 242325.0 0.042
SE: Standard Error, AUC0–300, area under the secretory curve between time 0–300 min
doi:10.1371/journal.pone.0121087.t001
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Insulin secretion and action indices
The insulin secretion and action indices (mean±SE) are presented in Table 1. HOMA-β levels
were higher in obese women than in healthy women; 111.6±10.6 vs 67.4±8.9, p = 008, for the
obese and healthy women respectively. AUC0–300 Insulin/glucose ((μU/mL)/(mg/dL)min) lev-
els were higher in the obese women than in the healthy control women; 0.4±0.03 vs 0.23±0.02,
P<0.001, for the obese and healthy women respectively. HOMA-IR levels were higher in the
obese women than in the healthy control women; 2.9±0.3 vs 1.2±0.2, p<0.001, for the obese
and healthy women respectively. Matsuda index was lower in the obese women than in the
healthy control women; 5.3±0.4 vs 13.1±1.1, P<0.001, for the obese and healthy
women respectively.
Correlations
There were significant association between GH secretion indices and the different adiposity, in-
sulin secretion, insulin action and ghrelin secretion indices (Table 2).
The linearity of associations with GH secretion indices were additionally explored by means
of penalized cubic regression splines (Fig. 3).
Due to the significant correlations between the different adiposity indices, insulin secretion
indices, insulin action indices and ghrelin, multivariate analysis was used with both linear re-
gression and generalized additive (GAM) models in order to quantitatively assess the individu-
al contribution that each predictive measure made to explain the variability among the values
of GH secretion indices (fasting, peak, AUC) while in the presence of the remaining predictors.
Fig 1. Mean±SE plasma glucose (a; mg/dL), insulin (b; μU/mL) GH (c; μg/L) and total ghrelin levels (d; pg/mL) in normal (grey) and obese women
(black) during the prolongued oral glucose tolerance test. * p<0.05 between normal and obese women at that time point. Insulin was higher in the obese
women than in the healthy control women after the 300 min OG (Fig. 1b). GH was lower in the the obese women than in the healthy control women after OG
(Fig. 1c). The AUC of GH (μg/Lmin) between 0 and 300 min was lower in the obese patients than in the controls; 249.8±41.8 vs 490.4±74.6, P = 0.001, for
the obese patients and controls respectively. Peak GH (μg/L) levels were lower in the obese than in the healthy women, 3.3±0.5 vs 6.6±0.8 p<0.001, for the
obese and healthy women respectively. Total ghrelin was lower in the obese women than in the healthy women after OG (Fig. 1d). The AUC of total ghrelin
(pg/mLmin) between 0 and 300 min was lower in the obese patients than in the controls; 240995.5±11094.2 vs 340797.5±37757.5, P = 0.042, for the obese
and healthy women respectively (Fig. 2).
doi:10.1371/journal.pone.0121087.g001
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In the presence of IGF-I, adiposity indices (waist circumference), insulin sensitivity (Matsuda
index) and ghrelin secretion (ghrelin AUC/100.000), only ghrelin AUC remained a significant
predictor for fasting GH and Peak GH, and was borderline significant for GH AUC (Table 3).
Discussion
By studying a relative large cohort of women, we have found that after OG in healthy and
obese women, both ghrelin and GH secretion are decreased. There was a significant association
between the GH secretion indices and the different adiposity, insulin secretion, insulin action
indices and ghrelin secretion. After multivariate analysis, only ghrelin secretion remained a sig-
nificant predictor for both fasting and peak GH. These data suggest that circulating ghrelin is
an important regulator of GH secretion after OG in women, and that the decreased GH secre-
tion in obesity after OG is probably due to the altered ghrelin secretion found in obese women.
Taken together, these data further reinforces the importance of metabolic signals and nutri-
tional status in GH secretion which in turn could influence the perpetuation and/or further de-
velopment of the obese state.
The primary cause of impaired GH secretion in obesity could be an altered hypothalamus,
abnormal pituitary function, or a perturbation of the peripheral signals acting at either the pi-
tuitary or hypothalamic level. There are three important peripheral signals that could partici-
pate in the altered GH secretion of obesity, leptin, insulin and ghrelin. Iranmanesh et al studied
GH secretion during 6 h. after OG in men [23]. They found that glucose-suppressed nadir GH
concentrations and postglucose rebound-like peak GH release in men are strongly determined
by selective metabolic surrogates, especially including adipose visceral fat, adiponectin, leptin
Table 2. Correlations between GH secretion indices (Peak: μg/L and AUC: μg/Lmin) and the different adiposity indices, insulin secretion
indices, insulin action indices and ghrelin (Nadir: pg/mL and AUC: pg/mLmin) secretion in the entire group of healthy and obese women.
GH Fasting GH Peak GH AUC0–300
Rho p Rho p Rho p
IGF-1 -0.062 0.635 0.279 0.028 0.323 0.010
BMI -0.214 0.095 -0.564 <0.001 -0.499 <0.001
Waist circumference -0.197 0.124 -0.560 <0.001 -0.465 <0.001
Total body Fat (%) -0.227 0.076 -0.479 <0.001 -0.414 0.001
Total body Fat mass -0.241 0.059 -0.561 <0.001 -0.500 <0.001
Leptin -0.218 0.094 -0.425 0.001 -0.419 0.001
Fasting glucose -0.287 0.024 -0.582 <0.001 -0.552 <0.001
Fasting Insulin -0.248 0.052 -0.482 <0.001 -0.511 <0.001
Homa-β -0.160 0.214 -0.220 0.086 -0.268 0.035
AUC Insulin0–300 -0.155 0.228 -0.408 0.001 -0.449 <0.001
AUC Insulin/Glucose0–300 -0.115 0.373 -0.245 0.055 -0.294 0.020
Homa-IR -0.252 0.059 -0.540 <0.001 -0.575 <0.001
QUICKI 0.242 0.059 0.523 <0.001 0.552 <0.001
Matsuda Index 0.243 0.057 0.553 <0.001 0.559 <0.001
Disposition index 0.213 0.097 0.468 <0.001 0.431 <0.001
Fasting Ghrelin 0.386 0.002 0.450 <0.001 0.443 <0.001
Nadir Ghrelin 0.401 0.001 0.341 0.007 0.371 0.003
Ghrelin AUC0–300 0.001 0.412 0.001 0.409 0.001 0.399
Rho: Spearman’s Rho correlation coefficient; AUC0–300, area under the secretory curve between time 0–300 min.
doi:10.1371/journal.pone.0121087.t002
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and sex hormone binding globulin (SHBG). Our data are in accordance with their suggestion
that the most likely mechanism of rebound GH secretion after glucose ingestion is delayed en-
dogenous ghrelin drive under waining somatostatin restraint. The best established action of ex-
ogenously administered ghrelin is its potent stimulation of pituitary GH secretion [9]. In
humans a GHSRmissense mutation, which impairs the constitutive activity of the GHS-R, is
associated with short stature [24]. Several studies have investigated the relationship between
ghrelin and GH secretion. Espelund et al. [25], did not find a correlation between ghrelin and
GH under fasting conditions. Avram et al. [10] did not observe any relationship with GH
under fed or fasting conditions. Their differing results may be connected with protocol differ-
ences, and also their study population included both men and women. Koutkia et al. [11]
found that there is a significant regularity in cosecretion between ghrelin and GH in the fasted
state; however, this was only found during the night. Misra et al. [12], using deconvolution
analysis for GH and total ghrelin in healthy adolescents and adolescents with anorexia, found
that fasting ghrelin is an independent predictor of basal GH secretion and GH secretory burst
frequency. In studies carried out on 8 healthy young men, Nass et al [13] found a significant re-
lationship between GH secretion peak amplitudes and mean circulating acylated ghrelin levels
during the fed condition. In agreement with our results in healthy and obese women, they con-
clude that under normal conditions in subjects given regular meals, endogenous ghrelin acts to
increase the amplitude of GH pulses. Studies in mice without the Ghrelin O-acyltransferase
gene (Mgoat) have found that an essential function of ghrelin in mice is elevation of GH levels
during severe calorie restriction, thereby preserving blood glucose and preventing death [26].
On the other hand, it has been recently found that with normal aging, endogenous acyl-ghrelin
levels are less tightly linked to GH regulation [27], indicating that the physiological role of
ghrelin on GH regulation is age dependent.
In experimental animals, leptin stimulates GH secretion [28] and in clinical studies exoge-
nous leptin failed to inhibit fasting-stimulated GH secretion [29]. The negative GH-leptin rela-
tionship observed in some studies probably reflects the known inverse correlation between
total body fat and GH. It has been found after oral glucose that fasting and initial GH secretion
and fasting leptin levels were higher in women than in men, suggesting that leptin does not
participate in the sexual dimorphism of GH secretion after oral glucose [30]. In addition,
Fig 2. Mean±SE plasmaGH AUC0–300 (pg/mLmin) and Ghrelin AUC0–300 (pg/mLmin) in normal (grey) and obese women (black) during the
prolongued oral glucose tolerance test. * p<0.05 between normal and obese women.
doi:10.1371/journal.pone.0121087.g002
Effect of Oral Glucose Administration on GH Release
PLOS ONE | DOI:10.1371/journal.pone.0121087 March 17, 2015 8 / 13
Table 3. Generalized additive regression (GAM) model for GH secretion indices (log-transformed).
Fasting GH (log(μg/L)) Peak GH (log(μg/L)) AUC0–300 GH (log(μUI/mLmin))
B SE p B SE p B SE p
Intercept -3.266 0.896 <0.001 2.398 0.846 0.007 5.871 0.897 <0.001
Age (years) 0.011 0.017 0.537 -0.012 0.008 0.148 -0.009 0.008 0.280
IGF-1* - - 0.993 - - 0.231 - - 0.138
Waist circumference* - - 0.149 -0.012 0.007 0.097 -0.005 0.008 0.491
Matsuda Index 0.098 0.055 0.080 - - 0.150 - - 0.139
GhrelinAUC0–300 (/100.000) 0.430 0.160 0.010 0.159 0.077 0.045 0.162 0.081 0.053
*Introduced as a non-linear term in the model
AUC0–300, area under the secretory curve between time 0–300 min; B, linear regression coefficient; SE, standard error
doi:10.1371/journal.pone.0121087.t003
Fig 3. Relationship between GH secretion indices (log-transformed) and IGF-I, waist circumference,
Matsuda index and Ghrelin AUC0–300 data. Univariate generalized additive regression (GAM) models.
A clear linear association between ghrelin AUC and the different indices of GH secretion (log-transformed)
was found (Fig. 3).
doi:10.1371/journal.pone.0121087.g003
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treatment with recombinant growth hormone in patients with growth hormone deficiency de-
creased fat mass and leptin levels [31]. Taken together, all these data are in accordance with
our results indicating that leptin does not participate in the decreased GH secretion in obesity.
Insulin treatment inhibits GH release and reduces mRNA expression of GH, GHRH receptor
and GHSR in primary cultures isolated from non-human primates [5]. In male mice, impaired
pulsatile GH secretion occurs alongside progressive weight gain and thus precedes the develop-
ment of obesity. In a similar way to our results in women, an inverse relationship between mea-
sures of pulsatile GH secretion and body weight, circulating levels of leptin and insulin has
been demonstrated in mice [32]. Many indices in the study by Iranmanesh et al [23] point to
insulin resistance (hyperinsulinemia) being involved in alterations in GH output, however, nei-
ther insulin concentrations nor HOMA-IR correlated with rebound GH secretion. Moreover,
in the interesting study by Cornford et al, the reduction in GH secretion did not correlate with
the increased insulin levels [8]. Other factors like sex steroids, GHRH, somatostatin, IGF-1,
and IGFBP-1 could modulate ghrelin's control of GH secretion, as has been found in in healthy
elderly men [33]. In addition, free fatty acids have been found to participate in GH hyposecre-
tion in obesity [34].
The suppression of GH secretion in obesity may have important metabolic impact. We be-
lieve that this study employing multivariate analysis with both linear regression and general-
ized additive model strongly suggests that ghrelin secretion is an important peripheral
regulator of GH secretion after oral glucose in healthy and obese women. The relationship be-
tween ghrelin, which increases food intake, and GH found during the late fed state would be
beneficial to humans, as the anabolic changes induced by GH requires the presence of adequate
nutrition [13, 25]. The findings of this study reveal that there is a significant correlation be-
tween ghrelin and GH secretion after OG in obese women, suggesting that the decreased ghre-
lin secretion in obesity is one of the mechanisms responsible for altered GH secretion in
obesity. The recovery of the GH IGF-1 axis after weight loss suggests an acquired defect; how-
ever the decreased stimulation of GH release in obese subjects may promote the retention of fat
mass, and contribute to perpetuation of the obese state. In premenopausal women with obesity,
peak GH is inversely associated with intramyocellular and intrahepatic lipids. This suggests
that low GHmay contribute to insulin resistance in obesity through effects on muscle and
intrahepatic lipids [35]. In the long-term, the functional GH deficiency could lead to a vicious
circle, and to deterioration of the beta cell mass, and participating in the development of diabe-
tes [36]. OG as a GH stimulus could have important clinical implications, as suggested by Iran-
manesh et al [23]. This GH stimulus could be employed in clinical practice, and may provide a
low risk means of evaluating endogenously regulated GH secretion without requiring the injec-
tion of insulin, GHRH, GHRP, or arginine in childhood, pregnancy or frail older adults.
Because our study was not interventional and the analysis is based on correlation, we cannot
completely exclude the existence of one common or several separate factors that control both
GH release and circulating ghrelin levels simultaneously. Therefore, a possible role for insulin
as a common regulator of circulating ghrelin and GH after OG cannot be completely excluded,
even though the correlation between GH and ghrelin persisted after adjusting for insulin. An-
other limitation is that we did not measure acylated ghrelin. Although acylated ghrelin has
proved to be the biologically active form in the control of GH secretion, most of the leading
studies on the correlation between GH and ghrelin secretion have focused on the estimation of
total ghrelin [11, 12, 25, 37, 38] and there are concerns regarding the specificity of available
acyl-ghrelin assays and, more importantly, the stability of plasma acylated ghrelin once collect-
ed [39]. In this sense, acylated ghrelin levels have been found normal or increased [40–42] but
also decreased [43–45] in obesity. The present study has been done only in women, so the pres-
ent results should not be extrapolated to men.
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Conclusions
These data suggest that ghrelin secretion is an important regulator of GH secretion after oral
glucose in women, and that the decreased GH secretion of obesity after oral glucose is probably
due to the altered ghrelin levels found in obese patients.
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